Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,201.9
-3.3 (-0.10%)

 

  • STI Straits Times Index
    3,201.9
    -3.3 (-0.10%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,587.9
    -0.1 (-0.01%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,132.0
    5.1 (0.02%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,609.9
    27.3 (0.76%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    28,600.4
    -204.4 (-0.71%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,625.7
    -18.0 (-0.27%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,220.2M
  • Value: 903.1M
  • Rise: 156
  • Fall: 164
  • Unch: 431

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Hatten Land0.063-0.005
Raffles Edu0.063-0.008
Sinjia Land0.100+0.014
Beverly JCG0.001-
Jiutian Chemical0.089+0.002
BHG Retail Reit0.570-
AnAn Intl0.028+0.001
Broadway Ind0.210+0.020
Rex Intl0.360+0.015
VCPlus0.024-0.001

World Indices

World Indices
Name Last Change
Nasdaq 15,090.2 -125.5
HSI 26,132.0 +5.1
HSCEI 9,322.1 -34.8
Jakarta 6,625.7 -18.0
Nikkei 225 28,600.4 -204.4
SSE Comp 3,609.9 +27.3
Shanghai A 3,783.3 +28.6
Shanghai B 276.7 +1.0
KOSPI 3,020.5 +14.4

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Hyphens Pharma HYPHENS PHARMA INTL LIMITED
Quotes 10 Minutes Delayed. Updated at 25 Oct 2021 16:59
Last (SGD): 0.300 Change: +0.005 High: 0.300 Remarks: -
Change (%): +1.70 Low: 0.290
Open 0.290 Yesterday's Close 0.295
Buy Price 0.295 Sell Price 0.300
Buy Volume ('000) 3.1 Sell Volume ('000) 49.8
Cumulative Volume ('000) 52.1 Cumulative Value 15,146
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.02051 Trailing EPS (SGD) e 0.02062 NAV (SGD) b 0.1651
PE a 14.627 Trailing PE f 14.546 Price / NAV b 1.8171
Dividend (SGD) d 0.006200 Cash In Hand (SGD) g 0.1029 Issued & Paid-up Shares c 300,430,000
Dividend Yield (%) d 2.067 Price / Cash In Hand g 2.915 Treasury Shares h -
Beta - 75 Daysi 0.387 R-Squared - 75 Days(%)i 2.43 Market Cap (M) 90.129
Beta - 500 Daysi 0.457 R-Squared - 500 Days (%)i 1.30 Enterprise Value (M) 63.361
Piotroski F Score 4 Exchange Code 1J5 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 33.9123 6-Month VWAP 0.327 Free Float (%) 19.3
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Wholesale and Retail Trade - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Index Components FTSE ST Catalist Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. The figure pertains to the respective exchange the stock is listed on. Updated on 13 Sep 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Hyphens Pharma SGX 90.129 14.627 14.546 1.8171 2.067
Industry Medical & Biotechnology SGX 1,022.856 18.917 16.162 1.4406 1.911
Pharmaceuticals: Major SGX 89.528 2431.015 115.115 3.6804 0.694
Index FTSE ST Catalist Index SGX 64.009 30.086 23.254 1.4336 1.820
Local Peer IX Biopharma SGX 175.349 - - 8.1597 -
Local Peer Pharmesis Intl SGX 3.105 - - 0.2663 -
Global Peer JOHNSON & JOHNSON NYSE 430,989.626 29.291 24.105 - 2.431
Global Peer PFIZER INC NYSE 241,984.740 25.165 18.293 3.4548 3.520
Global Peer ELI LILLY AND COMPANY NYSE 233,166.619 37.646 38.409 36.1813 1.214
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 206,730.946 25.611 23.011 3.8254 2.270
Global Peer MERCK & CO INC NYSE 205,420.676 29.068 36.873 6.1699 3.055
Global Peer ABBVIE INC NYSE 192,870.025 42.333 29.272 15.3448 4.430
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 191,442.103 59.901 50.767 12.2124 1.879
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 187,909.086 29.161 26.395 17.9730 1.269
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 127,993.536 - - 3.4773 3.226
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 126,144.845 8.986 18.216 1.6821 2.712
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC CO LTD (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), VIATRIS INC (NASDAQ), REPLIGEN CORP (NASDAQ), HANSOH PHARMACEUTICAL GROUP CO LTD (HKEx), INNOVENT BIOLOGICS INC (HKEx), CANSINO BIOLOGICS INC (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), ORGANON & CO (NYSE), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), SINOPHARM GROUP CO. LTD. (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), CUREVAC NV (NASDAQ), REMEGEN CO LTD (HKEx), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), ALLAKOS INC (NASDAQ), HYGEIA HEALTHCARE HLDGS CO LTD (HKEx), HUTCHMED (CHINA) LIMITED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), SHANGHAI PHARMACEUTICALS HOLDING CO (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), AKESO INC (HKEx), SHANGHAI JUNSHI BIOSCIENCES CO LTD (HKEx), CHINA MEDICAL SYSTEM HLDGS LTD (HKEx), GUANGZHOU BAIYUNSHAN PHARMACEUTICAL (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), INNOCARE PHARMA LTD (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), CHINA RESOURCES PHARMACEUTICAL GR (HKEx), CARSGEN THERAPEUTICS HLDGS LTD (HKEx), NEKTAR THERAPEUTICS (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), CHINA GRAND PHARMACEUTICAL & HEALTH (HKEx), SIMCERE PHARMACEUTICAL GRP LTD (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), OPKO HEALTH INC (NASDAQ), CHINA TRADITIONAL CHINESE MED HLDGS (HKEx), ATAI LIFE SCIENCES NV (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), ERASCA INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), ADC THERAPEUTICS SA (NYSE), EVEREST MEDICINES LTD (HKEx), QUANTERIX CORPORATION (NASDAQ), SHANGHAI HENLIUS BIOTECH INC (HKEx), AMNEAL PHARMACEUTICALS INC (NYSE), IGM BIOSCIENCES INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), SHENZHEN HEPALINK PHARMACEUTICAL (HKEx), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), SSY GROUP LIMITED (HKEx), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), CSTONE PHARMACEUTICALS (HKEx), OCUMENSION THERAPEUTICS (HKEx), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), UNITED LABORATORIES INTL HLDGS LTD (HKEx), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), PROCAPS GROUP S A (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), IMMUNOTECH BIOPHARM LTD (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), BEIJING TONG REN TANG CHINESE MEDIC (HKEx), ZYMEWORKS INC (NYSE), ATEA PHARMACEUTICALS INC (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), ABBISKO CAYMAN LTD (HKEx), Kimia Farma Tbk. (IDX), ICOSAVAX INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), SCICLONE PHARMACEUTICALS (HLDGS) LT (HKEx), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), KRONOS BIO INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), CK LIFE SCIENCES INTL HLDG (HKEx), TENAYA THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ANTENGENE CORP LTD (HKEx), MIND MEDICINE (MINDMED) INC (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), PETIQ INC (NASDAQ), ANNEXON INC (NASDAQ), GH RESEARCH PLC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), CHINA SHINEWAY PHARMACEUTICAL GR (HKEx), POINT BIOPHARMA GLOBAL INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), VERU INC (NASDAQ), BEYONDSPRING INC (NASDAQ), TRANSCENTA HOLDING LTD (HKEx), ORIC PHARMACEUTICALS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), GRITSTONE BIO INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), HUA MEDICINE (HKEx), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), PHARVARIS NV (NASDAQ), ZHAOKE OPHTHALMOLOGY LTD (HKEx), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), MIRUM PHARMACEUTICALS INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), EVOLUS INC (NASDAQ), AC IMMUNE SA (NASDAQ), PYXIS ONCOLOGY INC (NASDAQ), IGBB (Bursa), EVELO BIOSCIENCES INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), MINK THERAPEUTICS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), PROVENTION BIO INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), CLENE INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), 89BIO INC (NASDAQ), RACE ONCOLOGY LTD (ASX), EYEPOINT PHARMACEUTICALS INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), CLEARSIDE BIOMEDICAL INC (NASDAQ), DAWNRAYS PHARMACEUTICAL HLDGS (HKEx), THERATECHNOLOGIES INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), TOT BIOPHARM INTL CO LTD (HKEx), CODIAK BIOSCIENCES INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), CYBIN INC (NYSE American), FUSION PHARMACEUTICALS INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), BSTEAD (Bursa), NEXIMMUNE INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), XOMA CORP (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), ATHENEX INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), DURECT CORP (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), PHARMA (Bursa), TCR2 THERAPEUTICS INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), FUSEN PHARMACEUTICAL CO LTD (HKEx), OVID THERAPEUTICS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), ANNOVIS BIO INC (NYSE American), GAMIDA CELL LTD (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), IMMUNIC INC (NASDAQ), OBSEVA SA (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), TRICIDA INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), MUSTANG BIO INC (NASDAQ), IP (SET), PHASEBIO PHARMACEUTICALS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), ALZAMEND NEURO INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), EYENOVIA INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), CHINA BIOTECH SERVICES HLDGS LTD (HKEx), HOOKIPA PHARMA INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), POLYPID LTD (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), NOVAN INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), ZHONGZHI PHARMACEUTICAL HLDGS LTD (HKEx), LOGICBIO THERAPEUTICS INC (NASDAQ), ENTERA BIO LTD (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), ODONATE THERAPEUTICS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), Merck Tbk. (IDX), LANTERN PHARMA INC (NASDAQ), GENPREX INC (NASDAQ), LANNETT CO INC (NYSE), KOTRA (Bursa), DARE BIOSCIENCE INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), MEDIWOUND LTD (NASDAQ), CRESO PHARMA LTD (ASX), YUMANITY THERAPEUTICS INC (NASDAQ), CHARMACY PHARMACEUTICAL CO LTD (HKEx), IMARA INC (NASDAQ), NEW RAY MEDICINE INTL HLDG LTD (HKEx), CLARUS THERAPEUTICS HLDGS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), GALECTO INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), MANNATECH INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), Phapros Tbk. (IDX), OCUPHIRE PHARMA INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), NOVA (Bursa), PAK FAH YEOW INTERNATIONAL (HKEx), NEW CENTURY HEALTHCARE HLDGS CO LTD (HKEx), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), EXOPHARM LTD (ASX), ABVC BIOPHARMA INC (NASDAQ), SYNAPTOGENIX INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), BIOHLDG (Bursa), SANAI HEALTH INDUSTRY GP CO LTD (HKEx), INVION LTD (ASX), WAI YUEN TONG MEDICINE HOLDINGS LTD (HKEx), MODERN CHINESE MEDICINE GRP CO LTD (HKEx), SHENZHEN NEPTUNUS INTERLONG BIO-TEC (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), RENOVORX INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), ASSERTIO HOLDINGS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), BONE BIOLOGICS CORP (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), BAUDAX BIO INC (NASDAQ), PURAPHARM CORPORATION LIMITED (HKEx), MEDLAB CLINICAL LIMITED (ASX), SEQLL INC (NASDAQ), PALLA PHARMA LTD (ASX), ARIDIS PHARMACEUTICAL INC (NASDAQ), PHARMAXIS (ASX), CNS PHARMACEUTICALS INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), XORTX THERAPEUTICS INC (NASDAQ), DERMATA THERAPEUTICS INC (NASDAQ), PASITHEA THERAPEUTICS CORP (NASDAQ), VALLON PHARMACEUTICALS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), ACER THERAPEUTICS INC (NASDAQ), JCT (SET), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), EXTRAWELL PHARMACEUTICAL HLDGS (HKEx), SUNZEN (Bursa), ONCOSIL MEDICAL LIMITED (ASX), NLS PHARMACEUTICS LTD (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), ACRUX (ASX), PAINREFORM LTD (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), IMMURON LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), NANJING SINOLIFE UNITED COMPANY LTD (HKEx), PETROS PHARMACEUTICALS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), CHINA SXT PHARMACEUTICALS INC (NASDAQ), PA SHUN INTERNATIONAL HOLDINGS LTD (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days ---
20 Days --0.010
-3.23 %
Medium Term Return 3 Months --0.015
-4.76 %
6 Months 0.006-0.030
-7.27 %
1 Year 0.006-0.085
-20.52 %
Long Term Return 2 Years 0.016+0.105
+62.05 %
3 Years 0.022+0.085
+49.77 %
Annualised Return Annualised --
+14.41 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.285 - 0.430 Change From 1 Year Low +0.015 % Change From 1 Year Low (%) +5.26
Change From 1 Year High -0.130 % Change From 1 Year High (%) -30.23
2 Years Range 0.180 - 0.625 Change From 2 Years Low +0.120 % Change From 2 Years Low (%) +66.67
Change From 2 Years High -0.325 % Change From 2 Years High (%) -52.00
5 Years Range 0.160 - 0.625 Change From 5 Years Low +0.140 % Change From 5 Years Low (%) +87.50
Change From 5 Years High -0.325 % Change From 5 Years High (%) -52.00
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapores leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Groups regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.The Groups core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

IPO Performance

Listing Date 18 May 2018 Full Subscription Rate (x) 17.91
No of Placement Shares (M) 23.79 No of Public Offer Shares (M) 3.00 Public Offer Subscription Rate (x) 151.99
IPO Price (SGD) a 0.260 First Day Close (SGD) a 0.275 First Week Close (SGD) a 0.260
Current vs IPO Price (%) +15.38 First Day Gain (%) +5.77 First Week Gain (%) -
Notes:
  1. Adjusted for the following: 23,790,000 Placement Shares do not include the 2,810,000 Reserved Shares.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2020 Dec 2020 Part 1(8.67 MB)
Annual Report 2019 Dec 2019 Part 1(6.40 MB)
Annual Report 2018 Dec 2018 Part 1(7.14 MB)
IPO Prospectus
IPO Prospectus 2018 May 2018 Part 1(2.57 MB)
Part 2(0.27 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
25 Oct 2021 0.290 0.300 0.290 0.300 52,100 0.2907
22 Oct 2021 0.295 0.295 0.295 0.295 5,500 0.2950
21 Oct 2021 0.295 0.295 0.290 0.290 37,200 0.2947
20 Oct 2021 0.295 0.295 0.295 0.295 - -
19 Oct 2021 0.300 0.300 0.295 0.295 106,400 0.2951
18 Oct 2021 0.300 0.300 0.295 0.300 68,500 0.2992
15 Oct 2021 0.300 0.305 0.300 0.305 70,700 0.3000
14 Oct 2021 0.295 0.295 0.295 0.295 20,000 0.2950
13 Oct 2021 0.295 0.295 0.295 0.295 95,100 0.2950
12 Oct 2021 0.300 0.300 0.300 0.300 - -
11 Oct 2021 0.295 0.300 0.295 0.300 202,400 0.2950
08 Oct 2021 0.295 0.300 0.295 0.295 27,500 0.2960
07 Oct 2021 0.290 0.290 0.290 0.290 2,000 0.2900
06 Oct 2021 0.295 0.295 0.290 0.290 105,500 0.2912
05 Oct 2021 0.290 0.295 0.290 0.295 51,000 0.2920
04 Oct 2021 0.295 0.295 0.295 0.295 167,900 0.2950
01 Oct 2021 0.295 0.295 0.295 0.295 - -
30 Sep 2021 0.295 0.295 0.295 0.295 300 0.2950
29 Sep 2021 0.300 0.300 0.295 0.295 31,700 0.2984
28 Sep 2021 0.310 0.310 0.305 0.310 231,000 0.3097
27 Sep 2021 0.295 0.310 0.290 0.310 159,300 0.2975
24 Sep 2021 0.295 0.295 0.290 0.290 40,000 0.2925
Summary
Current 2 Weeks
(12 Oct 2021 to 25 Oct 2021)
0.300 0.305 0.290 0.300 455,500 -
Previous 2 Weeks
(28 Sep 2021 to 11 Oct 2021)
0.310 0.310 0.290 0.300 819,300 -
4 Weeks from
(31 Aug 2021 to 27 Sep 2021)
0.305 0.305 0.290 0.310 1,175,700 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.